FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma

Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the U.S. Food and Drug Administration (FDA) granting ... Read More